Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart
Cumulative evidence indicates that mitochondrial dysfunction has a role in heart failure progression, but whether mitochondrial quality control mechanisms are involved in the development of cardiac dysfunction remains unclear. Here we show that cytosolic p53 impairs autophagic degradation of damaged...
Gespeichert in:
Veröffentlicht in: | Nature communications 2013-08, Vol.4 (1), p.2308-2308, Article 2308 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2308 |
---|---|
container_issue | 1 |
container_start_page | 2308 |
container_title | Nature communications |
container_volume | 4 |
creator | Hoshino, Atsushi Mita, Yuichiro Okawa, Yoshifumi Ariyoshi, Makoto Iwai-Kanai, Eri Ueyama, Tomomi Ikeda, Koji Ogata, Takehiro Matoba, Satoaki |
description | Cumulative evidence indicates that mitochondrial dysfunction has a role in heart failure progression, but whether mitochondrial quality control mechanisms are involved in the development of cardiac dysfunction remains unclear. Here we show that cytosolic p53 impairs autophagic degradation of damaged mitochondria and facilitates mitochondrial dysfunction and heart failure in mice. Prevalence and induction of mitochondrial autophagy is attenuated by senescence or doxorubicin treatment
in vitro
and
in vivo
. We show that cytosolic p53 binds to Parkin and disturbs its translocation to damaged mitochondria and their subsequent clearance by mitophagy. p53-deficient mice show less decline of mitochondrial integrity and cardiac functional reserve with increasing age or after treatment with doxorubicin. Furthermore, overexpression of Parkin ameliorates the functional decline in aged hearts, and is accompanied by decreased senescence-associated β-galactosidase activity and proinflammatory phenotypes. Thus, p53-mediated inhibition of mitophagy modulates cardiac dysfunction, raising the possibility that therapeutic activation of mitophagy by inhibiting cytosolic p53 may ameliorate heart failure and symptoms of cardiac ageing.
Damaged mitochondria are removed from cells through a process called mitophagy. Here, Hoshino
et al
. show that the cytosolic fraction of the protein p53 inhibits mitophagy by sequestering the mitophagy regulator Parkin, leading to impaired mitochondrial integrity and cardiac function in aged or damaged mouse hearts. |
doi_str_mv | 10.1038/ncomms3308 |
format | Article |
fullrecord | <record><control><sourceid>proquest_C6C</sourceid><recordid>TN_cdi_proquest_miscellaneous_1418364814</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1418364814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-e4805d62955a748dec6b665993d84d0454402931f52e8da7c21896c8a3be7e173</originalsourceid><addsrcrecordid>eNplkUtPxCAUhYnRqBnd-AMMiRujqUKBli7NxFdiogtdNwzcsYwtjEAX8-9Fx1eUDTeXL-cezkXogJIzSpg8d9oPQ2SMyA20WxJOC1qXbPNXvYP2Y1yQfFhDJefbaKfMVc1EtYsW01Xy0fdW46Vg2LrOzmyK-EGFF-uKAYxVCQwebPLLTj2vsHIGL4MffIL40daddyZY1WOzivPR6WS9y0o4dYAHP0bAHaiQ9tDWXPUR9j_vCXq6unyc3hR399e304u7QnPBUgFcEmGqshFC1Vwa0NWsqkTTMCO5IVxwTsqG0bkoQRpV65LKptJSsRnUkL81Qcdr3ezydYSY2sFGDX2vHGQ3LeVUsopLyjN69Add-DG47O6dqpuKkFJk6mRN6eBjDDBvl8EOKqxaStr3JbQ_S8jw4afkOMvpfaNfkWfgdA3E_OSeIfya-V_uDb2xka0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1417960025</pqid></control><display><type>article</type><title>Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart</title><source>Springer Nature OA Free Journals</source><creator>Hoshino, Atsushi ; Mita, Yuichiro ; Okawa, Yoshifumi ; Ariyoshi, Makoto ; Iwai-Kanai, Eri ; Ueyama, Tomomi ; Ikeda, Koji ; Ogata, Takehiro ; Matoba, Satoaki</creator><creatorcontrib>Hoshino, Atsushi ; Mita, Yuichiro ; Okawa, Yoshifumi ; Ariyoshi, Makoto ; Iwai-Kanai, Eri ; Ueyama, Tomomi ; Ikeda, Koji ; Ogata, Takehiro ; Matoba, Satoaki</creatorcontrib><description>Cumulative evidence indicates that mitochondrial dysfunction has a role in heart failure progression, but whether mitochondrial quality control mechanisms are involved in the development of cardiac dysfunction remains unclear. Here we show that cytosolic p53 impairs autophagic degradation of damaged mitochondria and facilitates mitochondrial dysfunction and heart failure in mice. Prevalence and induction of mitochondrial autophagy is attenuated by senescence or doxorubicin treatment
in vitro
and
in vivo
. We show that cytosolic p53 binds to Parkin and disturbs its translocation to damaged mitochondria and their subsequent clearance by mitophagy. p53-deficient mice show less decline of mitochondrial integrity and cardiac functional reserve with increasing age or after treatment with doxorubicin. Furthermore, overexpression of Parkin ameliorates the functional decline in aged hearts, and is accompanied by decreased senescence-associated β-galactosidase activity and proinflammatory phenotypes. Thus, p53-mediated inhibition of mitophagy modulates cardiac dysfunction, raising the possibility that therapeutic activation of mitophagy by inhibiting cytosolic p53 may ameliorate heart failure and symptoms of cardiac ageing.
Damaged mitochondria are removed from cells through a process called mitophagy. Here, Hoshino
et al
. show that the cytosolic fraction of the protein p53 inhibits mitophagy by sequestering the mitophagy regulator Parkin, leading to impaired mitochondrial integrity and cardiac function in aged or damaged mouse hearts.</description><identifier>ISSN: 2041-1723</identifier><identifier>EISSN: 2041-1723</identifier><identifier>DOI: 10.1038/ncomms3308</identifier><identifier>PMID: 23917356</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/80/39/2348 ; 692/308 ; 692/699/75 ; Aging - pathology ; Animals ; Cellular Senescence - drug effects ; Cytosol - metabolism ; Doxorubicin - adverse effects ; Embryo, Mammalian - pathology ; Fibroblasts - drug effects ; Fibroblasts - metabolism ; HCT116 Cells ; Heterozygote ; Humanities and Social Sciences ; Humans ; Mice ; Mice, Transgenic ; Mitochondria - drug effects ; Mitochondria - metabolism ; Mitochondria - ultrastructure ; Mitochondrial Degradation - drug effects ; multidisciplinary ; Myocardium - metabolism ; Myocardium - pathology ; Myocardium - ultrastructure ; Protein Binding - drug effects ; Protein Structure, Tertiary ; Protein Transport - drug effects ; Science ; Science (multidisciplinary) ; Tumor Suppressor Protein p53 - metabolism ; Ubiquitin-Protein Ligases - chemistry ; Ubiquitin-Protein Ligases - metabolism</subject><ispartof>Nature communications, 2013-08, Vol.4 (1), p.2308-2308, Article 2308</ispartof><rights>Springer Nature Limited 2013</rights><rights>Copyright Nature Publishing Group Aug 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-e4805d62955a748dec6b665993d84d0454402931f52e8da7c21896c8a3be7e173</citedby><cites>FETCH-LOGICAL-c453t-e4805d62955a748dec6b665993d84d0454402931f52e8da7c21896c8a3be7e173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/ncomms3308$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://doi.org/10.1038/ncomms3308$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41096,42165,51551</link.rule.ids><linktorsrc>$$Uhttps://doi.org/10.1038/ncomms3308$$EView_record_in_Springer_Nature$$FView_record_in_$$GSpringer_Nature</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23917356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoshino, Atsushi</creatorcontrib><creatorcontrib>Mita, Yuichiro</creatorcontrib><creatorcontrib>Okawa, Yoshifumi</creatorcontrib><creatorcontrib>Ariyoshi, Makoto</creatorcontrib><creatorcontrib>Iwai-Kanai, Eri</creatorcontrib><creatorcontrib>Ueyama, Tomomi</creatorcontrib><creatorcontrib>Ikeda, Koji</creatorcontrib><creatorcontrib>Ogata, Takehiro</creatorcontrib><creatorcontrib>Matoba, Satoaki</creatorcontrib><title>Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart</title><title>Nature communications</title><addtitle>Nat Commun</addtitle><addtitle>Nat Commun</addtitle><description>Cumulative evidence indicates that mitochondrial dysfunction has a role in heart failure progression, but whether mitochondrial quality control mechanisms are involved in the development of cardiac dysfunction remains unclear. Here we show that cytosolic p53 impairs autophagic degradation of damaged mitochondria and facilitates mitochondrial dysfunction and heart failure in mice. Prevalence and induction of mitochondrial autophagy is attenuated by senescence or doxorubicin treatment
in vitro
and
in vivo
. We show that cytosolic p53 binds to Parkin and disturbs its translocation to damaged mitochondria and their subsequent clearance by mitophagy. p53-deficient mice show less decline of mitochondrial integrity and cardiac functional reserve with increasing age or after treatment with doxorubicin. Furthermore, overexpression of Parkin ameliorates the functional decline in aged hearts, and is accompanied by decreased senescence-associated β-galactosidase activity and proinflammatory phenotypes. Thus, p53-mediated inhibition of mitophagy modulates cardiac dysfunction, raising the possibility that therapeutic activation of mitophagy by inhibiting cytosolic p53 may ameliorate heart failure and symptoms of cardiac ageing.
Damaged mitochondria are removed from cells through a process called mitophagy. Here, Hoshino
et al
. show that the cytosolic fraction of the protein p53 inhibits mitophagy by sequestering the mitophagy regulator Parkin, leading to impaired mitochondrial integrity and cardiac function in aged or damaged mouse hearts.</description><subject>631/80/39/2348</subject><subject>692/308</subject><subject>692/699/75</subject><subject>Aging - pathology</subject><subject>Animals</subject><subject>Cellular Senescence - drug effects</subject><subject>Cytosol - metabolism</subject><subject>Doxorubicin - adverse effects</subject><subject>Embryo, Mammalian - pathology</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - metabolism</subject><subject>HCT116 Cells</subject><subject>Heterozygote</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>Mitochondria - ultrastructure</subject><subject>Mitochondrial Degradation - drug effects</subject><subject>multidisciplinary</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>Myocardium - ultrastructure</subject><subject>Protein Binding - drug effects</subject><subject>Protein Structure, Tertiary</subject><subject>Protein Transport - drug effects</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Ubiquitin-Protein Ligases - chemistry</subject><subject>Ubiquitin-Protein Ligases - metabolism</subject><issn>2041-1723</issn><issn>2041-1723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNplkUtPxCAUhYnRqBnd-AMMiRujqUKBli7NxFdiogtdNwzcsYwtjEAX8-9Fx1eUDTeXL-cezkXogJIzSpg8d9oPQ2SMyA20WxJOC1qXbPNXvYP2Y1yQfFhDJefbaKfMVc1EtYsW01Xy0fdW46Vg2LrOzmyK-EGFF-uKAYxVCQwebPLLTj2vsHIGL4MffIL40daddyZY1WOzivPR6WS9y0o4dYAHP0bAHaiQ9tDWXPUR9j_vCXq6unyc3hR399e304u7QnPBUgFcEmGqshFC1Vwa0NWsqkTTMCO5IVxwTsqG0bkoQRpV65LKptJSsRnUkL81Qcdr3ezydYSY2sFGDX2vHGQ3LeVUsopLyjN69Add-DG47O6dqpuKkFJk6mRN6eBjDDBvl8EOKqxaStr3JbQ_S8jw4afkOMvpfaNfkWfgdA3E_OSeIfya-V_uDb2xka0</recordid><startdate>20130806</startdate><enddate>20130806</enddate><creator>Hoshino, Atsushi</creator><creator>Mita, Yuichiro</creator><creator>Okawa, Yoshifumi</creator><creator>Ariyoshi, Makoto</creator><creator>Iwai-Kanai, Eri</creator><creator>Ueyama, Tomomi</creator><creator>Ikeda, Koji</creator><creator>Ogata, Takehiro</creator><creator>Matoba, Satoaki</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7ST</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope></search><sort><creationdate>20130806</creationdate><title>Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart</title><author>Hoshino, Atsushi ; Mita, Yuichiro ; Okawa, Yoshifumi ; Ariyoshi, Makoto ; Iwai-Kanai, Eri ; Ueyama, Tomomi ; Ikeda, Koji ; Ogata, Takehiro ; Matoba, Satoaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-e4805d62955a748dec6b665993d84d0454402931f52e8da7c21896c8a3be7e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/80/39/2348</topic><topic>692/308</topic><topic>692/699/75</topic><topic>Aging - pathology</topic><topic>Animals</topic><topic>Cellular Senescence - drug effects</topic><topic>Cytosol - metabolism</topic><topic>Doxorubicin - adverse effects</topic><topic>Embryo, Mammalian - pathology</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - metabolism</topic><topic>HCT116 Cells</topic><topic>Heterozygote</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>Mitochondria - ultrastructure</topic><topic>Mitochondrial Degradation - drug effects</topic><topic>multidisciplinary</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>Myocardium - ultrastructure</topic><topic>Protein Binding - drug effects</topic><topic>Protein Structure, Tertiary</topic><topic>Protein Transport - drug effects</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Ubiquitin-Protein Ligases - chemistry</topic><topic>Ubiquitin-Protein Ligases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoshino, Atsushi</creatorcontrib><creatorcontrib>Mita, Yuichiro</creatorcontrib><creatorcontrib>Okawa, Yoshifumi</creatorcontrib><creatorcontrib>Ariyoshi, Makoto</creatorcontrib><creatorcontrib>Iwai-Kanai, Eri</creatorcontrib><creatorcontrib>Ueyama, Tomomi</creatorcontrib><creatorcontrib>Ikeda, Koji</creatorcontrib><creatorcontrib>Ogata, Takehiro</creatorcontrib><creatorcontrib>Matoba, Satoaki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Hoshino, Atsushi</au><au>Mita, Yuichiro</au><au>Okawa, Yoshifumi</au><au>Ariyoshi, Makoto</au><au>Iwai-Kanai, Eri</au><au>Ueyama, Tomomi</au><au>Ikeda, Koji</au><au>Ogata, Takehiro</au><au>Matoba, Satoaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart</atitle><jtitle>Nature communications</jtitle><stitle>Nat Commun</stitle><addtitle>Nat Commun</addtitle><date>2013-08-06</date><risdate>2013</risdate><volume>4</volume><issue>1</issue><spage>2308</spage><epage>2308</epage><pages>2308-2308</pages><artnum>2308</artnum><issn>2041-1723</issn><eissn>2041-1723</eissn><abstract>Cumulative evidence indicates that mitochondrial dysfunction has a role in heart failure progression, but whether mitochondrial quality control mechanisms are involved in the development of cardiac dysfunction remains unclear. Here we show that cytosolic p53 impairs autophagic degradation of damaged mitochondria and facilitates mitochondrial dysfunction and heart failure in mice. Prevalence and induction of mitochondrial autophagy is attenuated by senescence or doxorubicin treatment
in vitro
and
in vivo
. We show that cytosolic p53 binds to Parkin and disturbs its translocation to damaged mitochondria and their subsequent clearance by mitophagy. p53-deficient mice show less decline of mitochondrial integrity and cardiac functional reserve with increasing age or after treatment with doxorubicin. Furthermore, overexpression of Parkin ameliorates the functional decline in aged hearts, and is accompanied by decreased senescence-associated β-galactosidase activity and proinflammatory phenotypes. Thus, p53-mediated inhibition of mitophagy modulates cardiac dysfunction, raising the possibility that therapeutic activation of mitophagy by inhibiting cytosolic p53 may ameliorate heart failure and symptoms of cardiac ageing.
Damaged mitochondria are removed from cells through a process called mitophagy. Here, Hoshino
et al
. show that the cytosolic fraction of the protein p53 inhibits mitophagy by sequestering the mitophagy regulator Parkin, leading to impaired mitochondrial integrity and cardiac function in aged or damaged mouse hearts.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23917356</pmid><doi>10.1038/ncomms3308</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 2041-1723 |
ispartof | Nature communications, 2013-08, Vol.4 (1), p.2308-2308, Article 2308 |
issn | 2041-1723 2041-1723 |
language | eng |
recordid | cdi_proquest_miscellaneous_1418364814 |
source | Springer Nature OA Free Journals |
subjects | 631/80/39/2348 692/308 692/699/75 Aging - pathology Animals Cellular Senescence - drug effects Cytosol - metabolism Doxorubicin - adverse effects Embryo, Mammalian - pathology Fibroblasts - drug effects Fibroblasts - metabolism HCT116 Cells Heterozygote Humanities and Social Sciences Humans Mice Mice, Transgenic Mitochondria - drug effects Mitochondria - metabolism Mitochondria - ultrastructure Mitochondrial Degradation - drug effects multidisciplinary Myocardium - metabolism Myocardium - pathology Myocardium - ultrastructure Protein Binding - drug effects Protein Structure, Tertiary Protein Transport - drug effects Science Science (multidisciplinary) Tumor Suppressor Protein p53 - metabolism Ubiquitin-Protein Ligases - chemistry Ubiquitin-Protein Ligases - metabolism |
title | Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T21%3A54%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_C6C&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytosolic%20p53%20inhibits%20Parkin-mediated%20mitophagy%20and%20promotes%20mitochondrial%20dysfunction%20in%20the%20mouse%20heart&rft.jtitle=Nature%20communications&rft.au=Hoshino,%20Atsushi&rft.date=2013-08-06&rft.volume=4&rft.issue=1&rft.spage=2308&rft.epage=2308&rft.pages=2308-2308&rft.artnum=2308&rft.issn=2041-1723&rft.eissn=2041-1723&rft_id=info:doi/10.1038/ncomms3308&rft_dat=%3Cproquest_C6C%3E1418364814%3C/proquest_C6C%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1417960025&rft_id=info:pmid/23917356&rfr_iscdi=true |